CAR-NK Cell Therapy

About CytoImmune Therapeutics

CytoImmune Therapeutics is a private, clinical-stage biotech focused on developing off-the-shelf CAR-NK cell therapies for cancer. The company's core strength lies in its proprietary NK cell engineering platform, built upon decades of foundational research from its scientific founders, Drs. Caligiuri and Yu. With a seasoned leadership team experienced in cell therapy CMC and commercialization, and an in-house manufacturing capability, CytoImmune is positioned to advance allogeneic NK cell therapies through clinical development. Its strategy targets the significant limitations of current autologous CAR-T treatments, such as manufacturing complexity and patient accessibility.

About CiMaas

CiMaas is a private, preclinical-stage biotech developing adoptive cell therapies centered on Natural Killer (NK) cells for oncology. Its core technology involves a proprietary feeder cell system (F012) for large-scale expansion of potent, donor-derived NK cells, which can be used alone, combined with therapeutic antibodies, or engineered into CAR-NK products. With a strong scientific advisory board and recent non-dilutive grant funding, the company is translating its platform from preclinical validation into clinical development for a broad range of solid tumors.

Therapeutic Areas

Other Solid Tumors and Hematologic Malignancies Drugs